2,4,6-Trihydroxybenzaldehyde is an orally active NF-?B inhibitor. 2,4,6-Trihydroxybenzaldehyde shows anti-tumor activity, anti-cancer cell proliferative activity and anti-obesity activity[1][2][3].
2,4,6-Trihydroxybenzaldehyde inhibits adipocyte differentiation and lipid accumulation in 3T3-L1 cells[1].
2,4,6-Trihydroxybenzaldehyde down-regulates PPARγ, C/EBPα, SREBP-1c, and FAS protein expression levels[1].
2,4,6-Trihydroxybenzaldehyde (oral administration; 5 and 25 mg/kg for 13 weeks) reduces the HFD-induced increase in weight gain, reduces serum levels of glucose, triglycerides, and total cholesterol[1].
[1]. Kim KN, et al. 2,4,6-Trihydroxybenzaldehyde, a potential anti-obesity treatment, suppressed adipocyte differentiation in 3T3-L1 cells and fat accumulation induced by high-fat diet in C57BL/6 mice. Environ Toxicol Pharmacol. 2015 Mar;39(2):962-8.
[2]. Marton A, et al. Vanillin Analogues o-Vanillin and 2,4,6-Trihydroxybenzaldehyde Inhibit NF?B Activation and Suppress Growth of A375 Human Melanoma. Anticancer Res. 2016 Nov;36(11):5743-5750.
[3]. Forester SC, et al. Gut metabolites of anthocyanins, gallic acid, 3-O-methylgallic acid, and 2,4,6-trihydroxybenzaldehyde, inhibit cell proliferation of Caco-2 cells. J Agric Food Chem. 2010 May 12;58(9):5320-7.